medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-25-73-79medalphabet-4030Research ArticleСтатьиСовременные представления о пустулёзном псориазе: патогенез, диагностика, лечениеCurrent concepts of pustular psoriasis: pathogenesis, diagnosis, treatmenthttps://orcid.org/0000-0002-0238-6563ШатохинаЕ. А.ShatokhinaE. A.

Шатохина Евгения Афанасьевна - д.м.н., профессор кафедры дерматовенерологии и косметологии, ФГБУ ДПО «ЦГМА» Управления делами Президента РФ; ведущий научный сотрудник, ФГБУ «МНОИ МГУ им. М.В. Ломоносова».

Москва

Evgeniya A. Shatokhina - DM Sci (habil.), professor at Dept of Dermatovenereology and Cosmetology, Central State Medical Academy» Department of Presidential Affairs of the Russian Federation; leading researcher, Medical Research and Educational Institute of Lomonosov Moscow State University.

Moscow

e.a.shatokhina@gmail.comhttps://orcid.org/0000-0001-5313-0624ЕгошинаИ. Г.EgoshinaI. G.

Егошина Ирина Геннадьевна - врач-дерматовенеролог, заведующая отделением.

Кемерово

Irina G. Egoshina - dermatovenereologist, head of Dept.

Kemerovo

gratis72@mail.ruhttps://orcid.org/0009-0004-3764-4034Бридан-РостовскаяА. С.Bridan-RostovskaуaA. S.

Бридан-Ростовская Анна Сергеевна - ординатор кафедры дерматовенерологии и косметологии.

Москва

Anna S. Bridan-Rostovskaya - resident at Dept of Dermatovenereology and Cosmetology.

Moscow

abridan@bk.ruhttps://orcid.org/0000-0002-5044-5265КругловаЛ. С.KruglovaL. S.

Круглова Лариса Сергеевна - д.м.н., профессор, заведующий кафедрой дерматовенерологии и косметологии.

Москва

Larisa S. Kruglova - DM Sci (habil.), professor, head of Dept of Dermatovenereology and Cosmetology.

Moscow

kruglovals@mail.ruФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации; ФГБУ «Медицинский научно-образовательный институт Московского государственного университета им. М.В. Ломоносова»РоссияCentral State Medical Academy» Department of Presidential Affairs of the Russian Federation; Medical Research and Educational Institute of Lomonosov Moscow State UniversityRussian FederationГУ «Кузбасский клинический кожно-венерологический диспансер»РоссияKuzbass Clinical Dermatovenerological DispensaryRussian FederationФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy» Department of Presidential Affairs of the Russian FederationRussian Federation202406122024025Дерматология (2)7379Copyright © Шатохина Е.А., Егошина И.Г., Бридан-Ростовская А.С., Круглова Л.С., 20242024Шатохина Е.А., Егошина И.Г., Бридан-Ростовская А.С., Круглова Л.С.Shatokhina E.A., Egoshina I.G., Bridan-Rostovskaуa A.S., Kruglova L.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4030

Псориаз – хроническое заболевание кожи, имеющее разнообразные клинические формы. Редкие варианты пустулезного псориаза связаны с доминированием в патогенезе врожденных и аутовоспалительных иммунных реакций, ведущую роль в которых играет цитокин IL-36. Перспективы терапии генерализованного пустулёзного псориаза связаны с использованием ингибиторов активности этого цитокина. Данные по эффективности лечения генерализованного пустулезного псориаза ингибиторами IL-17A ограничены, хотя препараты более доступны для практической деятельности. Продемонстрирована серия клинических случаев успешного использования нетакимаба в терапии генерализованного пустулёзного псориаза.

Psoriasis is a chronic skin disease with a variety of clinical forms. Rare variants of pustular psoriasis are associated with the dominance in the pathogenesis of innate and autoinflammatory immune reactions, the leading role in which is played by the cytokine IL-36. Prospects for therapy of generalized pustular psoriasis are associated with the use of inhibitors of the activity of this cytokine. Data on the efficacy of treatment of generalized pustular psoriasis with IL-17A inhibitors are limited, although the drugs are more readily available in practice. A series of clinical cases of successful use of netakimab in the therapy of generalized pustular psoriasis is demonstrated.

пустулезный псориазгенетикаIL-36IL-17Aинтерлейкин 36интерлейкин 17Aаутовоспалениегенно-инженерная биологическая терапиянетакимабpustular psoriasisgeneticsIL-36IL-17Ainterleukin 36interleukin 17Aautoinflammationbiological drugsnetakimabReferencesSarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin. Istanb. 2016;3:79–82.Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin. Istanb. 2016;3:79–82.Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019;20:1475.Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019;20:1475.Круглова Л.С, Бакулев Л. А., Коротаева Т.В, и др., «Псориаз», 2022 г.Kruglova L. S., Bakulev L. A., Korotaeva T. V., et al., “Psoriasis”, 2022. (In Russ.).Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin. Dermatol. 2007;25:535–546.Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin. Dermatol. 2007;25:535–546.Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev. Clin. Immunol. 2019;15:907–919.Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev. Clin. Immunol. 2019;15:907–919.Bissonnette R, et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J. Dermatol. Sci. 2017;85:20–26.Bissonnette R, et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J. Dermatol. Sci. 2017;85:20–26.Twelves S, et al. Clinical and genetic differences between pustular psoriasis subtypes. J. Allergy Clin. Immunol. 2019;143:1021–1026.Twelves S, et al. Clinical and genetic differences between pustular psoriasis subtypes. J. Allergy Clin. Immunol. 2019;143:1021–1026.Bangale-Daflapurkar S, Danve A. Pustular psoriasis of pregnancy successfully treated with cyclosporine. Am. J. Ther. 2016;23: e1250–e1252.Bangale-Daflapurkar S, Danve A. Pustular psoriasis of pregnancy successfully treated with cyclosporine. Am. J. Ther. 2016;23: e1250–e1252.Owczarczyk-Saczonek A, Znajewska-Pander A, Owczarek W, Maciejewska-Radomska A, Placek W. Clinicopathologic retrospective analysis of annular pustular psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat. 2018;27:215–219.Owczarczyk-Saczonek A, Znajewska-Pander A, Owczarek W, Maciejewska-Radomska A, Placek W. Clinicopathologic retrospective analysis of annular pustular psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat. 2018;27:215–219.Huang YW, Tsai TF. Juvenile-onset pustular psoriasis: case series and literature review. Br. J. Dermatol. 2020;182:816–817.Huang YW, Tsai TF. Juvenile-onset pustular psoriasis: case series and literature review. Br. J. Dermatol. 2020;182:816–817.Sanchez NP, Perry HO, Muller SA, Winkelmann RK. Subcorneal pustular dermatosis and pustular psoriasis. A clinicopathologic correlation. Arch. Dermatol. 1983;119:715–721.Sanchez NP, Perry HO, Muller SA, Winkelmann RK. Subcorneal pustular dermatosis and pustular psoriasis. A clinicopathologic correlation. Arch. Dermatol. 1983;119:715–721.Uppala R, Tsoi LC, Harms PW, Wang B, Billi AC, Maverakis E, Michelle Kahlenberg J, Ward NL, Gudjonsson JE. «Autoinflammatory psoriasis»-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307–317.Uppala R, Tsoi LC, Harms PW, Wang B, Billi AC, Maverakis E, Michelle Kahlenberg J, Ward NL, Gudjonsson JE. «Autoinflammatory psoriasis»-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307–317.Круглова Л. С., Моисеев С. В. Блокада интерлейкина-17 – новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017;2:5–12.Kruglova L. S., Moiseev S. V. Blockade of interleukin-17 – new horizons of efficacy and safety in the treatment of psoriasis. Clinical pharmacology and therapy. 2017;2:5–12. (In Russ.).Johnston A, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 2017;140:109–120.Johnston A, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 2017;140:109–120.Navarini AA, et al. European consensus statement on phenotypes of pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:1792–1799.Navarini AA, et al. European consensus statement on phenotypes of pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:1792–1799.Onoufriadis A, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 2011;89:432–437.Onoufriadis A, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 2011;89:432–437.Boutet MA, et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin. Exp. Immunol. 2016;184:159–173.Boutet MA, et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin. Exp. Immunol. 2016;184:159–173.Aksentijevich I, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009;360:2426–2437.Aksentijevich I, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009;360:2426–2437.Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017;49:1–8.Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017;49:1–8.Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J. Women’s Health. 2018;10:109–115.Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J. Women’s Health. 2018;10:109–115.Ross MG, Tucker DC, Hayashi RH. Impetigo herpetiformis as a cause of postpartum fever. Obstet. Gynecol. 1984;64:49S-51S.Ross MG, Tucker DC, Hayashi RH. Impetigo herpetiformis as a cause of postpartum fever. Obstet. Gynecol. 1984;64:49S-51S.Yamashita T, et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up. Int J. Dermatol. 2019;58:350–353.Yamashita T, et al. An effective and promising treatment with adalimumab for impetigo herpetiformis with postpartum flare-up. Int J. Dermatol. 2019;58:350–353.Choon SE, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J. Dermatol. 2014;53:676–684.Choon SE, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J. Dermatol. 2014;53:676–684.Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br. J. Dermatol. 1968;80:771–793.Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br. J. Dermatol. 1968;80:771–793.Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br. J. Dermatol. 1971;85:407– 411.Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br. J. Dermatol. 1971;85:407– 411.Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch. Dermatol. 1991;127:1339–1345.Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch. Dermatol. 1991;127:1339–1345.Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int. J. Mol. Sci. 2016;17:1214.Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int. J. Mol. Sci. 2016;17:1214.Larsabal M, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br. J. Dermatol. 2019;180:647–656.Larsabal M, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br. J. Dermatol. 2019;180:647–656.Ozturk G, et al. Generalized pustular eruptions due to terbinafine. Cutan. Ocul. Toxicol. 2012;31:81–84.Ozturk G, et al. Generalized pustular eruptions due to terbinafine. Cutan. Ocul. Toxicol. 2012;31:81–84.Gammoudi R, et al. Acute generalized exanthematous pustulosis induced by oxacillin confirmed by patch testing. Contact Dermat. 2018;79:108–110. 31.Webster GF. Pustular drug reactions. Clin. Dermatol. 1993;11:541–543.Gammoudi R, et al. Acute generalized exanthematous pustulosis induced by oxacillin confirmed by patch testing. Contact Dermat. 2018;79:108–110. 31.Webster GF. Pustular drug reactions. Clin. Dermatol. 1993;11:541–543.Абдулганиева Д. И., Бакулев А. Л., Белоусова Е. А., Знаменская Л. Ф., Коротаева Т. В., Круглова Л. С., Кохан М. М., Лила А. М., Хайрутдинов В. Р., Халиф И. Л., Хобейш М. М. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;3:4–18.Abdulganieva D. I., Bakulev A. L., Belousova E. A., Znamenskaya L. F., Korotaeva T. V., Kruglova L. S., Kokhan M. M., Lila A. M., Khairutdinov V. R., Khalif I. L., Khobeish M. M. Draft interdisciplinary recommendations for diagnostics, methods for assessing the degree of activity, therapeutic efficacy and the use of genetically engineered biological drugs in patients with combined immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease). Modern Rheumatology. 2018;3:4–18. (In Russ.).Saeki H, et al. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid. J. Dermatol. 2008;35:601–603. 33.Vasconcellos JB, et al. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. Bras. Dermatol. 2016;91:137–139.Saeki H, et al. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid. J. Dermatol. 2008;35:601–603. 33.Vasconcellos JB, et al. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. Bras. Dermatol. 2016;91:137–139.Соколовский Е. В., Круглова Л. С., Понич Е. С. "Болевые" точки системной терапии биологическими препаратами при псориазе. Российский журнал кожных и венерических болезней. 2015; 6:32–38.Sokolovsky E. V., Kruglova L. S., Ponich E. S. "Pain" points of systemic therapy with biological drugs for psoriasis. Russian Journal of Skin and Venereal Diseases. 2015; 6:32–38. (In Russ.).Jiyad Z, Moriarty B, Creamer D, Higgins E. Generalized pustular psoriasis associated with Epstein-Barr virus. Clin. Exp. Dermatol. 2015; 40: 146–148.Jiyad Z, Moriarty B, Creamer D, Higgins E. Generalized pustular psoriasis associated with Epstein-Barr virus. Clin. Exp. Dermatol. 2015; 40: 146–148.Yoneda K, Matsuoka-Shirahige Y, Demitsu T, Kubota Y. Pustular psoriasis precipitated by cytomegalovirus infection. Br. J. Dermatol. 2012; 167: 1186–1189.Yoneda K, Matsuoka-Shirahige Y, Demitsu T, Kubota Y. Pustular psoriasis precipitated by cytomegalovirus infection. Br. J. Dermatol. 2012; 167: 1186–1189.Pouessel G, et al. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Pediatr. Dermatol. 2007; 24: 401–404.Pouessel G, et al. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Pediatr. Dermatol. 2007; 24: 401–404.Miot HA, Miot LD, Lopes PS, Haddad GR, Marques SA. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J. Eur. Acad. Dermatol. Venereol. 2009; 23: 1173–1177.Miot HA, Miot LD, Lopes PS, Haddad GR, Marques SA. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J. Eur. Acad. Dermatol. Venereol. 2009; 23: 1173–1177.Wilsmann-Theis, D. et al. Palmoplantar pustulosis – a cross-sectional analysis in Germany. Dermatol. Online J.23 (2017).Wilsmann-Theis, D. et al. Palmoplantar pustulosis – a cross-sectional analysis in Germany. Dermatol. Online J.23 (2017).Bachelez H, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N. Engl. J. Med. 2019; 380: 981–983. doi: 10.1056/NEJMc1811317. [DOI] [PubMed] [Google Scholar]Bachelez H, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N. Engl. J. Med. 2019; 380: 981–983. doi: 10.1056/NEJMc1811317. [DOI] [PubMed] [Google Scholar]McDermott MF, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR 1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999; 97: 133–144.McDermott MF, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR 1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999; 97: 133–144.Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 2006; 305: 127–160.Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 2006; 305: 127–160.Huffmeier U, Watzold M, Mohr J, Schon MP, Mossner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br. J. Dermatol. 2014; 170: 202–204.Huffmeier U, Watzold M, Mohr J, Schon MP, Mossner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br. J. Dermatol. 2014; 170: 202–204.Henry CM, et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016; 14: 708–722.Henry CM, et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016; 14: 708–722.Clancy DM, Henry CM, Sullivan GP, Martin SJ. Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. FEBS J. 2017; 284: 1712–1725.Clancy DM, Henry CM, Sullivan GP, Martin SJ. Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. FEBS J. 2017; 284: 1712–1725.Vigne S, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011; 118: 5813–5823.Vigne S, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011; 118: 5813–5823.Mutamba S, Allison A, Mahida Y, Barrow P, Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur. J. Immunol. 2012; 42: 607–617.Mutamba S, Allison A, Mahida Y, Barrow P, Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur. J. Immunol. 2012; 42: 607–617.Arakawa A, et al. Unopposed IL-36 activity promotes clonal CD 4(+) T-cell responses with IL-17A production in generalized pustular psoriasis. J. Invest. Dermatol. 2018; 138: 1338–1347.Arakawa A, et al. Unopposed IL-36 activity promotes clonal CD 4(+) T-cell responses with IL-17A production in generalized pustular psoriasis. J. Invest. Dermatol. 2018; 138: 1338–1347.Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br. J. Dermatol. 2004; 150: 1009–1012.Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br. J. Dermatol. 2004; 150: 1009–1012.Imafuku S, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J. Dermatol. 2016; 43: 1011–1017.Imafuku S, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J. Dermatol. 2016; 43: 1011–1017.Young K. Z. Sarkar MK, Gudjonsson JE. Pathophysiology of generalized pustular psoriasis. Exp Dermatol. 2023 Aug;32(8):1194–1203.Young K. Z. Sarkar MK, Gudjonsson JE. Pathophysiology of generalized pustular psoriasis. Exp Dermatol. 2023 Aug;32(8):1194–1203.Robinson A, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 2012; 67: 279–288.Robinson A, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 2012; 67: 279–288.Torii H, Nakagawa H, Japanese Infliximab Study Investigators Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J. Dermatol. 2011; 38: 321–334.Torii H, Nakagawa H, Japanese Infliximab Study Investigators Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J. Dermatol. 2011; 38: 321–334.Kimura U, et al. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis. J. Dermatol. 2012; 39: 286–287.Kimura U, et al. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis. J. Dermatol. 2012; 39: 286–287.Wendling D, et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Jt. Bone Spine. 2008; 75: 315–318.Wendling D, et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Jt. Bone Spine. 2008; 75: 315–318.Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016; 152: 825–828.Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016; 152: 825–828.Bissonnette R, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J. Eur. Acad. Dermatol. Venereol. 2014; 28: 1298–1305.Bissonnette R, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J. Eur. Acad. Dermatol. Venereol. 2014; 28: 1298–1305.Husson, B. et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J. Eur. Acad. Dermatol. Venereol.10.1111/jdv.16265 (2020).Husson, B. et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J. Eur. Acad. Dermatol. Venereol.10.1111/jdv.16265 (2020).Mrowietz U, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J. Am. Acad. Dermatol. 2019; 80:1344–1352.Mrowietz U, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J. Am. Acad. Dermatol. 2019; 80:1344–1352.Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br.J. Dermatol. 2015; 173: 239–241.Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br.J. Dermatol. 2015; 173: 239–241.Skendros P, et al. Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition. Br. J. Dermatol. 2017; 176: 212–215.Skendros P, et al. Successful response in a case of severe pustular psoriasis after interleukin-1beta inhibition. Br. J. Dermatol. 2017; 176: 212–215.Mansouri B, Kivelevitch D, Campa M, Menter A. Palmoplantar pustular psoriasis unresponsive to the interleukin-1beta antagonist canakinumab. Clin. Exp. Dermatol. 2016; 41: 324–326.Mansouri B, Kivelevitch D, Campa M, Menter A. Palmoplantar pustular psoriasis unresponsive to the interleukin-1beta antagonist canakinumab. Clin. Exp. Dermatol. 2016; 41: 324–326.Инструкция к препарату Эфлейра (нетакимаб), https://www.rlsnet.ru/drugs/efleira-80199Instructions for the drug Efleira (netakimab), https://www.rlsnet.ru/drugs/efleira-80199

The authors declare that there are no conflicts of interest present.